All In Biotech

Drug Trial Radar · NCT01710176

Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

550

Actual

Start

Jun 1, 2011

Primary completion

Jun 30, 2024

Study completion Jun 30, 2024

Sponsor

Lead sponsor
Italian Sarcoma GroupResearch network
Sponsor type
Research network
Collaborators
French Sarcoma Group; Grupo Espanol de Investigacion en Sarcomas
First posted
Oct 19, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized Phase III clinical trial in the setting of localized high-risk soft tissue sarcomas (STS). This study will compare a standard neoadjuvant chemotherapy with epirubicin plus ifosfamide versus a histology-driven chemotherapy, i.e. a chemotherapy tailored to the specific histology within the family of adult STS. Chemotherapy will be administered for 3 cycles. There will be five histological groups (representing 80% of STS), as follows: leiomyosarcoma, myxoid liposarcoma with hypercellularity (round cell MLPS), synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST) and undifferentiated pleomorphic sarcoma. The histology-driven chemotherapy for these groups will be, respectively, gemcitabine plus dacarbazine, trabectedin, high-dose ifosfamide, ifosfamide plus etoposide, gemcitabine plus docetaxel. Other histological groups will also be included and registered, but treated only by standard chemotherapy. Patients who have already undergone definitive surgery will receive treatment post-operatively and patients needing a re-excision after inadequate surgery will be treated as patients in the two groups, but of course will not be evaluable for response. A centralized pathological review will be performed. Radiological response will be evaluated according to RECIST and to Choi criteria. Pathological response will also be recorded. The endpoint will be disease-free survival (DFS) and, secondarily, overall survival (OS) of patients receiving standard chemotherapy versus those receiving histotype-tailored chemotherapy. Additional aims will be to compare the probability of response of standard vs histotype-tailored chemotherapy and to determine the radiological and pathological response with standard chemotherapy vs tailored chemotherapy in each different histological group. Another aim will be to validate the response (both radiological and pathological) to preoperative chemotherapy as a surrogate endpoint for DFS and OS. Three hundred patients will be randomized over a 3-years period, from a pool of 400-450 registered patients. Translational research will be performed. Areas of research will include identification and validation of the potential predictive markers for each histological subgroups. The study is designed to verify the statistical hypothesis that histotype-tailored approach is associated, overall, with a 30% reduction in the hazard of relapse. However, in each different histological group, the effect of histotype-tailored chemotherapy, as compared to standard chemotherapy, can be different. To address this weakness an orthogonal study of response to chemotherapy as a surrogate of DFS and OS has been introduced into the trial. This study intends to extensively investigate the response (radiological and pathological) to preoperative chemotherapy and to validate it as a surrogate endpoint by showing that it correlates with disease free survival and overall survival.

Conditions

  • Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults

Interventions

  • epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)Drug

  • gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)Drug

  • trabectedin 1.3 mg/m2Drug

  • high-dose ifosfamide 14 g/m2, given in in 14 daysDrug

  • etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)Drug

  • gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the effect on disease-free survival of full-dose standard chemotherapy with histotype-tailored chemotherapy within the context of an integrated strategy for high risk soft tissue sarcomas typical of the adult.Time frame: 5 years

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Irccs Centro Di Riferimento Oncologico (Cro) -

    Aviano (PN), Italy

  • Irccs Istituto Ortopedico Rizzoli (Ior) -

    Bologna, Italy

  • Pres.Ospedal.Spedali Civili Brescia -

    Brescia, Italy

  • Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori -

    Meldola (FC), Italy

  • Irccs Istituto Europeo Di Oncologia (Ieo) -

    Milan, Italy

  • Irccs Istituto Nazionale Dei Tumori (Int)

    Milan, Italy

  • Irccs Istituto Nazionale Tumori Fondazione Pascale -

    Naples, Italy

  • Irccs Istituto Oncologico Veneto (Iov)

    Padova, Italy

  • Irccs Istituto Regina Elena (Ifo)

    Roma, Italy

  • Irccs Istituto Clinico Humanitas -

    Rozzano (MI), Italy

  • Presidio Sanitario Gradenigo Di Torino

    Torino, Italy

  • Fondazione Del Piemonte Per L'Oncologia Ircc Di Candiolo -

    Candiolo, TO, Italy

  • Hospital Vall D'Hebron

    Barcelona, Spain

  • Hospital Clínico de Malaga

    Málaga, Spain

  • Hospital Son Espases

    Palma de Mallorca, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.